Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03002935 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of Orally Administered BPM31510 in Healthy Subjects
A Phase 1 study, sponsored by BPGbio.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT03002935 is a Phase 1 study that has completed, run by BPGbio. The registered enrollment target is 25 participants.
The verdict
NCT03002935, a Phase 1 study, has completed, sponsored by BPGbio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is an open-label, Phase I study of the bioavailability and safety of BPM31510 administered orally in healthy subjects dosed 3 times daily for 14 days. The last study dose is administered on Day 15 (one morning dose only). The study will consist of 25 subjects.
Interventions
- DRUG BPM31510 Oral Nanosuspension 4%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-01 |
| Est. Completion | 2017-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03002935
The ClinicalTrials.gov registry entry for NCT03002935 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BPGbio, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BPM31510 Oral Nanosuspension 4% is the first listed.
NCT03002935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03002935 about?
NCT03002935 is a clinical study titled "A Safety Study of Orally Administered BPM31510 in Healthy Subjects". This is an open-label, Phase I study of the bioavailability and safety of BPM31510 administered orally in healthy subjects dosed 3 times daily for 14 days. The last study dose is administered on Day 15 (one morning dose only). The study will consist of 25 subjects.
What is the current status of trial NCT03002935?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2017-01. Estimated completion is 2017-03.
What interventions are being tested in trial NCT03002935?
The interventions under investigation include: BPM31510 Oral Nanosuspension 4% (DRUG).
Who is sponsoring clinical trial NCT03002935?
This trial is sponsored by BPGbio, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.